Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”

Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”

Abstract Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications—methadone, buprenorphine, and extended-release injectable naltrexone,— are efficacious for treating opioid use disorder (OUD). However, the utility of these medications is limited...

Full description

Bibliographic Details
Main Authors: Matisyahu Shulman, Roger Weiss, John Rotrosen, Patricia Novo, Elizabeth Costello, Edward V. Nunes
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Addiction Science & Clinical Practice
Subjects:
Opioid use disorder
Buprenorphine
Naltrexone
Clinical trials
Online Access:https://doi.org/10.1186/s13722-021-00223-z

Internet

https://doi.org/10.1186/s13722-021-00223-z

Similar Items